Summary

Global Acute Respiratory Distress Syndrome Market has been forecasted to reach up to USD 2.36 billion by 2032, up from US$ 1.23 billion in 2023 at a compound annual growth rate of 7.49% with the base year from 2024 to 2032.

Acute Respiratory Distress Syndrome is a state in which the organs fail and the lungs, specifically the alveoli, are flooded with fluids that reduce the delivery of oxygen to the vital organs. It is commonly attributed to diseases and conditions like sepsis, pneumonia, or toxic inhalation injuries. The symptoms of the disease are difficulties in breathing, hypotension, and increased rate of respiration. Mechanical ventilation, the use of intravenous fluids and administration of inhaled medications are commonly used in managing ARDS. The occurrence is coupled with more than 3 million participants globally resulting from air pollution and the breath-taking of toxic gases. According to WHO estimates, 3 Million individuals develop ARDS annually all over the world.

Promptly recognizing acute respiratory distress syndrome is crucial for initiating effective lung-protective ventilation strategies. However, diagnosis is often delayed, with reported under-diagnosis rates as high as 40%. The likelihood of diagnosis increases with disease severity. The current clinical criteria have low specificity, and no biomarkers are available for diagnosis, but active research is ongoing. The indirect injuries such as severe bacterial infection, sepsis, severe bleeding, low blood pressure requiring blood transfusions, and pancreas inflammation. In addition, it is mentioned that the global market for Acute Respiratory Distress Syndrome was $1004.4 million in 2022.

Acute respiratory distress syndrome may result from exposure to environmental pollutants like air pollution and toxins, as well as from chronic conditions such as heart disease, diabetes, and obesity. Poorly managed chronic conditions increase the risk of developing acute respiratory distress syndrome. Beaufort is an FDA-approved medication for preventing lower respiratory tract disease caused by respiratory syncytial virus (RSV) in neonates and infants up to two years of age who are at risk of severe RSV disease.

The impact of Acute Respiratory Distress Syndrome on healthcare systems worldwide. It highlights increased admissions to critical care units and hospitals, with statistics from countries such as Australia, France, and the U.S. The importance of increasing investment in healthcare for Acute Respiratory Distress Syndrome to improve patient outcomes and reduce the burden of potentially fatal conditions is emphasized, along with the need for intensive medical intervention and advanced medical technologies. The global healthcare infrastructure investment is expected to experience significant growth by 2025, particularly in the Middle East, Africa, and Asia.


United States Acute Respiratory Distress Syndrome Market

The USA acute respiratory distress syndrome market is growing due to the increasing prevalence of acute lung injury, driven by factors such as the patient pool with ARDS. Companies across the United States have shifted their focus toward this therapeutic area to meet the unmet need for the acute respiratory distress syndrome treatment regimen. Emerging therapies are focused on treating acute respiratory distress syndrome and are expected to impact market size significantly. According to the WHO, 200,000 people in the United States are affected by ARDS every year. Chronic lung diseases like asthma are a significant cause of ARDS, with over 34 million people in the U.S. living with chronic lung diseases like asthma and COPD.


Global Acute Respiratory Distress Syndrome Company Analysis

Prominent players in the Acute Respiratory Distress Syndrome Market are Silence Therapeutics plc, Gilead Sciences Inc., Terumo Corporation, Getinge AB, Livanova Plc, Medtronic, Inc., Fresenius Se & Co. KGAA, Nipro, and Pfizer Inc.
Acute Respiratory Distress Syndrome Company New
Jan 2024: LivaNova PLC is winding down its ACS Business Unit to focus on its core Cardiopulmonary and Neuromodulation Business Units. The wind-down process is expected to be completed by the end of 2024.
Feb 2024: Silence Therapeutics received a $10 million milestone payment from AstraZeneca to begin a phase 1 clinical trial for their siRNA collaboration.
March 2024: Gilead Sciences, Inc. and Xilio Therapeutics, Inc. announced exclusive license agreements for Xilio's tumor-activated IL-12 program, XTX301.
March 2024: Terumo Blood and Cell Technologies partnered with the CiRA Foundation to develop automated iPS cell manufacturing.
March 2024: Getinge has announced the U.S. launch of the Corin Operating Table and Ezea Surgical Light at AORN.
March 2024: The FDA has approved Medtronic's Evolut FX+ TAVR system for treating severe aortic stenosis. This system retains the benefits of the earlier Evolut TAVR platform and allows easier coronary access.
April 2024, Pfizer Inc. has reported successful results from Phase 3 clinical trials for ABRYSVO, a single-dose vaccine designed for adults aged 18 to 59 at risk of severe RSV-associated LRTD.
In December 2022, Terumo Corp. and Kyowa Kirin Co. launched "G-Lasta Subcutaneous Injection 3.6 mg BodyPod" in Japan.


Type – Market is divided into 2 viewpoints

1. Diagnosis
2. Treatment


End User – Market is divided into 4 viewpoints

1. Hospitals
2. Specialty clinics
3. Home healthcare
4. Others


Countries – Market is divided into 25 Country Acute Respiratory Distress Syndrome Industry

1. North America

1.1 United States
1.2 Canada

2. Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey

3. Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4. Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 United Arab Emirates
5.3 South Africa


Key Players: All key players have been covered from 4 points

• Overviews
• Recent Developments
• Product Portfolio
• Revenue


Company Analysis:

1. Silence Therapeutics plc
2. Gilead Seiences Inc.
3. Terumo Corporation
4. Getinge AB
5. Livanova Plc
6. Medtronic, Inc.
7. Fresenius Se & Co. KGAA
8. Nipro
9. Pfizer Inc.

ページTOPに戻る

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamic

4.1 Growth Drivers
4.2 Challenges
4.3 Opportunities


5. Global Acute Respiratory Distress Syndrome Market

6. Global Acute Respiratory Distress Syndrome Market Share Analysis

6.1 By Types
6.2 By End User
6.3 By Countries


7. Type

7.1 Diagnosis
7.2 Treatment


8. End User

8.1 Hospitals
8.2 Specialty clinics
8.3 Home healthcare
8.4 Others


9. Countries

9.1 North America

9.1.1 United States
9.1.2 Canada

9.2 Europe

9.2.1 France
9.2.2 Germany
9.2.3 Italy
9.2.4 Spain
9.2.5 United Kingdom
9.2.6 Belgium
9.2.7 Netherlands
9.2.8 Turkey

9.3 Asia Pacific

9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 South Korea
9.3.5 Thailand
9.3.6 Malaysia
9.3.7 Indonesia
9.3.8 Australia
9.3.9 New Zealand

9.4 Latin America

9.4.1 Brazil
9.4.2 Mexico
9.4.3 Argentina

9.5 Middle East & Africa

9.5.1 Saudi Arabia
9.5.2 United Arab Emirates
9.5.3 South Africa


10. Porter's Five Forces Analysis

10.1 Bargaining Power of Buyers
10.2 Bargaining Power of Suppliers
10.3 Degree of Competition
10.4 Threat of New Entrants
10.5 Threat of Substitutes


11. SWOT Analysis

11.1 Strength
11.2 Weakness
11.3 Opportunity
11.4 Threats


12. Key Players Analysis

12.1 Silence Therapeutics plc

12.1.1 Overviews
12.1.2 Recent Developments
12.1.3 Product Portfolio
12.1.4 Revenue

12.2 Gilead Sciences Inc.

12.2.1 Overviews
12.2.2 Recent Developments
12.2.3 Product Portfolio
12.2.4 Revenue

12.3 Terumo Corporation

12.3.1 Overviews
12.3.2 Recent Developments
12.3.3 Product Portfolio
12.3.4 Revenue

12.4 Getinge AB

12.4.1 Overviews
12.4.2 Recent Developments
12.4.3 Product Portfolio
12.4.4 Revenue

12.5 Livanova Plc.

12.5.1 Overviews
12.5.2 Recent Developments
12.5.3 Product Portfolio
12.5.4 Revenue

12.6 Medtronic, Inc.

12.6.1 Overviews
12.6.2 Recent Developments
12.6.3 Product Portfolio
12.6.4 Revenue

12.7 Fresenius SE & Co.KGAA

12.7.1 Overviews
12.7.2 Recent Developments
12.7.3 Product Portfolio
12.7.4 Revenue

12.8 Nipro

12.8.1 Overviews
12.8.2 Recent Developments
12.8.3 Product Portfolio
12.8.4 Revenue

12.9 Pfizer Inc.

12.9.1 Overviews
12.9.2 Recent Developments
12.9.3 Product Portfolio
12.9.4 Revenue